

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims

1. (Previously presented) A method for treating neoplasia in a mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor.

2. (Original) The method of Claim 1 wherein the neoplasia is selected from the group consisting of lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.


3. (Currently amended) A method for treating neoplasia in a subject mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor, wherein the matrix metalloproteinase inhibitor is selected from compounds of the group consisting of:

1)




N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

2)




1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

3)




N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

4)




N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

5)




N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide;

6)




N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

7)




N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

8)




N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

9)




N4-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)-, [2S-[N4(R*),2R*,3S*]]-;

10)



4-[(4'-chloro[1,1'-biphenyl]-4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid;

11)




N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide;

12) 6-demethyl-6-deoxy-4-dedimethylaminotetracycline;


- 13) 2- [1S- ([[2R,S)- acetylmercapto- 5- phthalimido]pentanoyl- L-leucyl)amino- 3- methylbutyl]imidazole;

14)




N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide monohydrochloride;

15)




N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4 (trifluoromethoxy) phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

16)




N-hydroxy-1-(2-methoxyethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide;

17)




1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

18)




4-[[4-(cyclohexylthio)phenyl]sulfonyl]-N-hydroxy-1-(2-propynyl)-4-piperidinecarboxamide monohydrochloride;

19)




4-[[4-(4-chlorophenoxy)phenyl]sulfonyl]tetrahydro-N-hydroxy-2H-pyran-4-carboxamide;

20)




N-hydroxy-4-[[4-(4-methoxyphenoxy)phenyl]sulfonyl]-1-(2-propynyl)-4-piperidinecarboxamide;

21)




1-cyclopropyl-4-[[4-[(4-fluorophenyl)thio]phenyl]sulfonyl]-N-hydroxy-4-piperidinecarboxamide;

22)




1-cyclopropyl-N-hydroxy-4-[[4-(phenylthio)phenyl]sulfonyl]-4-piperidinecarboxamide;

23)



tetrahydro-N-hydroxy-4-[[4-(4-pyridinylthio)phenyl]sulfonyl]-2H-pyran-4-carboxamide;

24)




tetrahydro-N-hydroxy-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-2H-pyran-4-carboxamide.

4. (Previously presented) A method for treating neoplasia in a mammal in need of such treatment, comprising treating said mammal with radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix


metalloproteinase inhibitor, wherein the matrix metalloproteinase inhibitor is selected from compounds of the group consisting of:

1)




N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

2)




1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

3)




N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidiny]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

4)




N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

5)




N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidiny]sulfonyl]benzamide;

6)




N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

7)




N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride;

8)




N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride;

9)




N4-[2,2-dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2-dihydroxy-3-(2-methylpropyl)-, [2S-[N4(R*),2R*,3S*]]-;

10)



4-[(4'-chloro[1,1'-iphenyl]-4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid;

11)




N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide;

12) 6-demethyl-6-deoxy-4-dedimethylaminotetracycline; and


13) 2-[1S-([(2R,S)-acetylmercapto-5-phthalimido]pentanoyl-L-leucyl)amino-3-methylbutyl]imidazole.

5. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-1-(4-methylphenyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

6. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




1-cyclopropyl-N-hydroxy-4-[[4-[4-(trifluoromethoxy)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

7. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-1-(phenylmethyl)-4-[[4-[4-(trifluoromethoxy)phenoxy]-1-piperidiny]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

8. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-1-(4-piperidinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride.

9. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-2,3-dimethoxy-6-[[4-[4-(trifluoromethyl)phenoxy]-1-piperidinyl]sulfonyl]benzamide.

10. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-1-(4-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride.

11. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-1-(3-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide dihydrochloride.

12. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




N-hydroxy-1-(2-pyridinylmethyl)-4-[[4-[4-(trifluoromethyl)phenoxy]phenyl]sulfonyl]-4-piperidinecarboxamide monohydrochloride.

13. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is




British Biotech BB-2516 (Marimastat), N4-[2,2- dimethyl-1-[(methylamino)carbonyl]propyl]-N1,2 -dihydroxy-3 (2-methylpropyl)-[2S- [N4(R*),2R*,3S*]]-).

14. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



Bayer Ag Bay-12-9566, 4-[(4'-chloro[1,1'- biphenyl]- 4-yl)oxy]-2-[(phenylthio)methyl]butanoic acid.

15. (Previously presented) The method of claim 3 wherein the matrix metalloproteinase inhibitor is



N-hydroxy-2,2-dimethyl-4-[[4-(4-pyridinyloxy)phenyl]sulfonyl]-3-thiomorpholinecarboxamide.

16. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is CollaGenex Pharmaceuticals CMT-3 (Metastat), 6-demethyl-6-deoxy-4-dedimethylaminotetracycline.

17. (Withdrawn) The method of claim 3 wherein the matrix metalloproteinase inhibitor is Chiroscience D-2163, 2- [1S- ((2R,S)-acetylmercapto- 5- phthalimido]pentanoyl- L- leucyl)amino- 3- methylbutyl]imidazole.

18. (Canceled) A combination comprising radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt thereof.

19. (Currently amended) The method of Claim 1 wherein the ~~combination~~ is radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor are administered in a sequential manner.

20. (Currently amended) The method of Claim 1 wherein the ~~combination~~ is radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor are administered in a substantially simultaneous manner.

21. (Currently amended) The method of Claim 3 wherein the ~~combination~~ is radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor are administered in a sequential manner.

22. (Currently amended) The method of Claim 3 wherein the ~~combination~~ is radiation therapy and a therapeutically effective amount of a matrix metalloproteinase inhibitor or pharmaceutically-acceptable salt of a matrix metalloproteinase inhibitor are administered in a substantially simultaneous manner.

23. (New) The method of claim 1 wherein the neoplasia is selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, adenosquamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choroid plexus papilloma/carcinoma, clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal sarcoma, endometrioid adenocarcinoma, ependymal, epitheloid, Ewing's sarcoma, fibrolamellar, focal nodular hyperplasia, gastrinoma, germ cell tumors, glioblastoma, glucagonoma, hemangioblastomas, hemangioendothelioma, hemangiomas, hepatic adenoma, hepatic adenomatosis, hepatocellular carcinoma, insulinoma, intraepithelial neoplasia, interepithelial squamous cell neoplasia, invasive squamous cell carcinoma, large cell carcinoma, leiomyosarcoma, lentigo maligna melanomas, malignant melanoma, malignant mesothelial tumors, medulloblastoma, medulloepithelioma, melanoma, meningeal, mesothelial, metastatic carcinoma, mucoepidermoid carcinoma, neuroblastoma, neuroepithelial adenocarcinoma nodular melanoma, oat cell carcinoma, oligodendroglial, osteosarcoma, pancreatic polypeptide, papillary serous adenocarcinoma, pineal cell, pituitary tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, serous carcinoma, small cell carcinoma, soft tissue carcinomas, somatostatin-secreting tumor, squamous carcinoma, squamous cell carcinoma, submesothelial, superficial spreading melanoma, undifferentiated carcinoma, uveal melanoma, verrucous carcinoma, vipoma, well differentiated carcinoma, and Wilm's tumor.

24. (New) The method of claim 1 wherein the neoplasia is lung cancer.

25. (New) The method of claim 1 wherein the neoplasia is breast cancer.

26. (New) The method of claim 1 wherein the neoplasia is bladder cancer.

27. (New) The method of claim 1 wherein the neoplasia is head and neck cancer.